Adverse effects of treatment with intravenous immunoglobulins for neurological diseases (Journal of Neurology (2006) 253, (SUPPL. 5) (75-79) DOI: 10.1007/s00415-006-5013-z);Adverse effects of treatment with intravenous immunoglobulins for neurological diseases

Journal of Neurology

Volumn 253, Issue SUPPL. 5, 2006, Pages 308-

  Wittstock, Matthias ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Adverse effects; Applications; Intravenous immunoglobulin therapy; Safety

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN 7S; IMMUNOGLOBULIN G; INTRIMUN;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; ATAXIA; CHILL; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DEEP VEIN THROMBOSIS; DIABETIC PATIENT; DISEASE EXACERBATION; DRUG CONTAMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROPENIA; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEART ARRHYTHMIA; HEART INFARCTION; HEMATOCRIT; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IMMUNOGLOBULIN A DEFICIENCY; LEUKOPENIA; MENINGISM; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PETECHIA; PHOTOPHOBIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; SKIN MANIFESTATION; STROKE; THORAX PAIN; THROMBOCYTOPATHY; URTICARIA; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VIRUS INFECTION; VOMITING;

EID: 33748979694     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0881-z     Document Type: Erratum

References (38)

1. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y (1998) IVIG adverse reactions: potential role of cytokins and vasoactive substances. Vox Sang 74:74-82
2. Ballow M, White W, Desbonnet C (1989) Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity intravenous immunoglobulin. J Allergy Clin Immunol 84:595-602
3. Basta M, Kirshbom P, Frank MM, Fries LF (1989) Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement -dependent immune damage in a guinea pig model. J Clin Invest 84:1974-1981
4. Berkovitch M, Dolinski G, Tauber T et al. (1999) Neuropenia as a complication of intravenous immunoglobulin (IVIg) therapy in children with immune thrombocytopenic pupura: common and no-alarming. Int J Immunopharmacol 31:411-415
5. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH (1996) Complications of intravenous gammaglobulin in neuromuscular diseases. Muscle Nerve 19:388-391
6. Brannagan TH, Nagle KJ, Lange DJ, Nagle KJ, Lange DJ, Rowland LP (1996) Complications of intravenous immune globuline treatment in neurologic disease. Neurology 47:674-677
7. Burks AW, Sampson HA, Buckley RH (1986) Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. N Engl J Med 314:560-564
8. Dalakas MC (1994) High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44:223-226
9. Dalakas MC (1997a) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126:721-730
10. Dalakas MC (1997b) Meningitis and skin reactions after intravenous immunoglobulin therapy. Ann Int Med 127:1130
11. Dalakas MC (1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22:1479-1497
12. Frank MM, Miletic VD, Jiang H (2000) Immunoglobulin in the control of complement action. Immunol Res 22:137-146
13. Frank MM, Basta M, Fries LF (1992) The effects of intravenous immune globulin on complement dependent immune damage of cells and tissues. Clin Immunol Immunopathol 62:S82-S86
14. Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75:83-85
15. Gold R, KV Toyka (2001) Immune therapy of neurological diseases. Unimed; Bremen-London, Boston
16. Hahn AF (2000) Intravenous immunoglobulin treatment in peripheral nerve disorders - indication, mechanisms of action and side-effects. Curr Opin Neurol 13:575-582
17. Hamdalla HHM, Hawkes CH, Spokes EG, Bamford JM, Goulding PJ (1996) Intravenous immunoglobulin in the Guillain Barré syndrome. BMJ 313:1399-1400
18. Hughes RAC, Svan AV, Cornblath DR et al. (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225-230
19. Kaveri SV, Dietrich G, Hurez V (1991) Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 86:192-198
20. Lawn N, Wijdicks EFM, Burrit MF (1998) Intravenous immune globulin and pseudohyponatremia. N Engl J Med 27:632
21. Lutz HU, Stammler P, Jelezarova E, Nater M, Spath PJ (1996) High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 88:184-193
22. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB (1992) Human antibodies reactive with synthetic autoantigens from T-cell receptor ß chain. Proc Natl Acad Sci (USA) 89:3325-3329
23. Rathko TA, Burnett DA, Foulke GE et al. (1995) University consortium panel, 1995. Recommendation for offlabel use of intravenously administered immunoglobulin preparations. Am J Med assoc 273:1865-1870
24. Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121:259-262
25. Silbert PL, Knezevic WV, Bridge DT (1992) Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 42:257-258
26. Sinclair NRS (1991) Fc-receptor-mediated immunomodulation. Immunol Today 12:46
27. Stangel M, Hartung HP, Marx P, Gold R (1997) Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 20:385-393
28. Stangel M, Hartung HP, Marx P, Gold R (1998) Intravenous immunglobulin treatment of neurological autoimmune diseases. J Neurol Sci 153:203-214
29. Stangel M, Kiefer R, Pette M; Smolka MN, Marx P, Gold R (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders. A prospective study. J Neurol 250:818-821
30. Steg RE, Lefkowitz DM (1994) Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 44:1180-1181
31. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR (1993) Acute renal failure resulting from intravenous immunglobulin therapy. Arch Neurol 50:137-139
32. The Dutch Guillain-Barré Study Group (1994) Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749-752
33. Vucic S, Siao Tick Chong P, Dawson KT, Cudkowicz M, Cros D (2004) Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol 52:141-144
34. Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing antimyosin antibody and by blocking complement deposition. Clin Exp Immunol 124:282-289
35. Whittam LR, Hay RJ, Hughes RAC (1997) Eczematous reactions of to human immune globulin. Br J Dermatol 137:481-482
36. Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RAC, Martin TD, McCrone P, Newsom-Davis J, Palace J, Rees JH, Rose MR, Scolding N, Webster ADB (2002) Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 72:440-448
37. Wittstock M, Benecke R, Zettl UK (2003) Therapy with intravenous immunoglobulins: Complications and side-effects. Eur Neurol 50:172-175
38. Wolberg AS, Kon RH, Monroe DM, Hoffman M (2000) Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 65:30-34